<DOC>
	<DOCNO>NCT00446147</DOCNO>
	<brief_summary>Although pyridoxine use empirically prevention capecitabine associate hand-foot syndrome ( HFS ) , efficacy need demonstrate prospective control trial . The investigator therefore perform prospective randomize double-blind study determine whether pyridoxine 200 mg/day prevent development HFS give concurrently capecitabine . The investigator also test ability pyridoxine treat primary occurrence grade 2-3 HFS .</brief_summary>
	<brief_title>Study Pyridoxine Hand-Foot Syndrome</brief_title>
	<detailed_description>Although pyridoxine use empirically prevention capecitabine associate HFS , efficacy need demonstrate prospective control trial . We estimate HFS rate placebo pyridoxine would 0.35 0.18 , respectively , therefore calculated sample size 345 patient would necessary detect hazard rate 80 % power ( β=0.2 ) two-sided significance level α=0.05 . We assume follow loss rate 10 % , thus require 380 patient randomize . Chemotherapy-naive patient gastrointestinal tract cancer schedule capecitabine-containing chemotherapy assign receive oral pyridoxine placebo randomize double-blind placebo control study . Pyridoxine 100 mg b.i.d prescribe patient pyridoxine group , identical placebo 100 mg b.i.d prescribe placebo group close envelop randomization . Patients stratify chemotherapy regimen : capecitabine alone ( X ) , capecitabine cisplatin ( XP ) , docetaxel , capecitabine , cisplatin ( DXP ) . Patients observe NCI CTC grade 2 3 HFS develop capecitabine-containing chemotherapy end . Patients placebo group develop grade 2 3 HFS randomize receive pyridoxine placebo next chemotherapy cycle determine whether pyridoxine could improve HFS , treatment continue 2 chemotherapy cycle .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<criteria>Gastrointestinal tract cancer patient treat capecitabinecontaining chemotherapy firstline treatment randomly allocate concurrent treatment pyridoxine placebo . All patient 18 70 year old Had Eastern Cooperative Oncology Group ( ECOG ) performance status 2 low An estimated life expectancy &gt; 3 month Adequate bone marrow function , include white blood cell ( WBC ) count ＞3500 cells/㎕ platelet count ＞100000/㎕ Adequate renal function ( serum creatinine concentration &lt; 1.5 mg/㎗ ) Adequate liver function ( serum bilirubin concentration &lt; 1.5 mg/㎗ , transaminase &lt; 3 time upper normal limit , serum albumin ＞2.5 mg/㎗ ) . Previous treatment HFS Hypersensitivity pyridoxine A combination malignancies Serious illnesses medical condition Immune suppression positive human immunodeficiency virus ( HIV ) serology Pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>hand-foot syndrome</keyword>
	<keyword>capecitabine</keyword>
	<keyword>pyridoxine</keyword>
	<keyword>prevention</keyword>
</DOC>